Real-world analysis demonstrates improved outcomes for patients with peripheral T-cell lymphoma, indicating the effectiveness of chidamide in maintenance therapy.
Key Points
Chidamide as maintenance therapy improved prognosis in patients with peripheral T-cell lymphoma.
Overall survival rate was not achieved, while the median progression-free survival was 54.8 months.